| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A phase II study
|
Rougier, P.
|
|
2000
|
36 |
8 |
p. 1016-1025
10 p.
|
artikel
|
| 2 |
Clinicopathological implication of cripto expression in early stage invasive cervical carcinomas
|
Ertoy, D
|
|
2000
|
36 |
8 |
p. 1002-1007
6 p.
|
artikel
|
| 3 |
Differential expression of the Ca2+ binding S100A6 protein in normal, preneoplastic and neoplastic colon mucosa
|
Stulı́k, J
|
|
2000
|
36 |
8 |
p. 1050-1059
10 p.
|
artikel
|
| 4 |
FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results
|
Pacini, P.
|
|
2000
|
36 |
8 |
p. 966-975
10 p.
|
artikel
|
| 5 |
Glyceraldehyde-3-phosphate dehydrogenase gene expression in human breast cancer
|
Révillion, F
|
|
2000
|
36 |
8 |
p. 1038-1042
5 p.
|
artikel
|
| 6 |
High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment
|
Kvinnsland, S.
|
|
2000
|
36 |
8 |
p. 976-982
7 p.
|
artikel
|
| 7 |
Histological response of cisplatin predicts patients' survival in oesophageal cancer and p53 protein accumulation in pretreatment biopsy is associated with cisplatin sensitivity
|
Shimada, Y.
|
|
2000
|
36 |
8 |
p. 987-993
7 p.
|
artikel
|
| 8 |
Mechanism of antimetastatic immunopotentiation by low-dose cyclophosphamide
|
Matar, P
|
|
2000
|
36 |
8 |
p. 1060-1066
7 p.
|
artikel
|
| 9 |
Natural history of untreated head and neck cancer
|
Kowalski, L.P.
|
|
2000
|
36 |
8 |
p. 1032-1037
6 p.
|
artikel
|
| 10 |
Opposite effects of antimicrotubule agents on c-myc oncogene expression depending on the cell lines used
|
Bourgarel-Rey, V
|
|
2000
|
36 |
8 |
p. 1043-1049
7 p.
|
artikel
|
| 11 |
p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer
|
Bouzourene, H.
|
|
2000
|
36 |
8 |
p. 1008-1015
8 p.
|
artikel
|
| 12 |
Regional chemotherapy in the treatment of advanced pancreatic cancer — is it relevant?
|
Lorenz, M.
|
|
2000
|
36 |
8 |
p. 957-965
9 p.
|
artikel
|
| 13 |
Significantly lower rates of BRCA1/BRCA2 founder mutations in Ashkenazi women with sporadic compared with familial early onset breast cancer
|
Gershoni-Baruch, R
|
|
2000
|
36 |
8 |
p. 983-986
4 p.
|
artikel
|
| 14 |
The Scottish and Manchester randomised trial of neo-adjuvant chemotherapy for advanced cervical cancer
|
Symonds, R.P.
|
|
2000
|
36 |
8 |
p. 994-1001
8 p.
|
artikel
|
| 15 |
Up-front chemotherapy with fotemustine (F)/cisplatin (CDDP)/etoposide (VP16) regimen in the treatment of 33 non-removable glioblastomas
|
Frenay, M
|
|
2000
|
36 |
8 |
p. 1026-1031
6 p.
|
artikel
|
Tijdschrift beschrijving